Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright

Neumora Therapeutics (NASDAQ:NMRA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $30.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Bank of America lowered their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Royal Bank of Canada lowered shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Neumora Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $1.69 on Friday. Neumora Therapeutics has a 1 year low of $1.60 and a 1 year high of $21.00. The stock has a market capitalization of $273.04 million, a price-to-earnings ratio of -0.90 and a beta of 2.50. The company’s 50 day simple moving average is $5.50 and its 200 day simple moving average is $9.83.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter in the prior year, the company posted ($1.14) earnings per share. As a group, analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Neumora Therapeutics by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after acquiring an additional 1,629 shares during the last quarter. SkyOak Wealth LLC increased its holdings in Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock valued at $212,000 after purchasing an additional 5,000 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics during the 4th quarter worth $61,000. Charles Schwab Investment Management Inc. lifted its holdings in Neumora Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock worth $7,464,000 after buying an additional 5,899 shares during the period. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $64,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.